HAART Failure

The communication by Donald Forsdyke in the Jan. 24 issue of The Scientist1 was quite interesting. However, I disagree that resistance is the primary factor in HAART [highly active antiretroviral therapy] failure. Obviously, if it were, there would be no long-term efficacies for HAART in HIV, and there are. For example, Garcia et al. reported that discontinuation of patients' HAART after one year of successful treatment is followed by a rapid rebound of viral load; this rapidly returns to undete

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The communication by Donald Forsdyke in the Jan. 24 issue of The Scientist1 was quite interesting. However, I disagree that resistance is the primary factor in HAART [highly active antiretroviral therapy] failure. Obviously, if it were, there would be no long-term efficacies for HAART in HIV, and there are. For example, Garcia et al. reported that discontinuation of patients' HAART after one year of successful treatment is followed by a rapid rebound of viral load; this rapidly returns to undetectable levels following reintroduction of the same treatment.2

Similarly, Finzi et al. reported that after HAART treatment for up to 30 months, replication-competent HIV was routinely recovered from resting CD4+ T lymphocytes, and the recovered virus generally did not show mutations associated with resistance to the relevant antiretroviral drug.3 Thus, it would seem that the failure of HAART to cure AIDS is not primarily a resistance problem, but a failure of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Maxwell Gordon

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo